Patents by Inventor Jonathan A. Pachter

Jonathan A. Pachter has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • 3, 4-Di-substituted cyclobutene-1,2-diones as CXC-chemokine receptor antagonists
    Publication number: 20030204085
    Abstract: Disclosed are compounds of the formula: 1
    Type: Application
    Filed: July 30, 2002
    Publication date: October 30, 2003
    Inventors: Arthur G. Taveras, Cynthia J. Aki, Richard W. Bond, Jianping Chao, Michael Dwyer, Johan A. Ferreira, Jonathan A. Pachter, John J. Baldwin, Bernd Kaiser, Ge Li, J. Robert Merritt, Kingsley H. Nelson, Laura L. Rokosz
  • Use of neurokinin receptor antagonists to treat androgen-dependent diseases
    Patent number: 6569872
    Abstract: Use of an antagonist selected from the group consisting of: (a) antagonists of neurokinin-1 (NK1), neurokinin-2 (NK2) and neurokinin-3 (NK3) receptors, (b) antagonists of NK1 and NK2 receptors, (c) antagonists of NK2 and NK3 receptors, (d) antagonists of NK1 and NK3 receptors, (e) antagonists of NK1 receptors, and (f) antagonists of NK2 to treat symptoms and disorders associated with a production and/or secretion of androgen. One aspect of the invention relates to the use of antagonists to suppress production/secretion of androgens in mammals suffering from an androgen-dependent disease, such as benign prostatic hyperplasia and prostatic carcinoma.
    Type: Grant
    Filed: May 7, 2002
    Date of Patent: May 27, 2003
    Assignee: Schering Corporation
    Inventors: Michael W. Leach, Mark R. Berardi, Elmer J. Mirro, Dineshwar Sinha, Jonathan A. Pachter, Mark E. Cartwright, Gregory A. Reichard
  • 3,4-Di-substituted cyclobutene-1,2-diones as CXC chemokine receptor antagonists
    Publication number: 20030097004
    Abstract: There are disclosed compounds of the formula 1
    Type: Application
    Filed: February 1, 2002
    Publication date: May 22, 2003
    Applicant: Schering Corporation
    Inventors: Arthur G. Taveras, Cynthia J. Aki, Richard W. Bond, Jianping Chao, Michael Dwyer, Johan A. Ferreira, Jonathan A. Pachter, John J. Baldwin, Bernd Kaiser, Ge Li, J. Robert Merritt, Kingsley H. Nelson, Laura L. Rokosz
  • Use of neurokinin receptor antagonists to treat androgen-dependent diseases
    Publication number: 20030092602
    Abstract: Use of an antagonist selected from the group consisting of: (a) antagonists of neurokinin-1 (NK1), neurokinin-2 (NK2) and neurokinin-3 (NK3) receptors, (b) antagonists of NK1 and NK2 receptors, (c) antagonists of NK2 and NK3 receptors, (d) antagonists of NK1 and NK3 receptors, (e) antagonists of NK1 receptors, and (f) antagonists of NK2 to treat symptoms and disorders associated with a production and/or secretion of androgen. One aspect of the invention relates to the use of antagonists to suppress production/secretion of androgens in mammals suffering from an androgen-dependent disease, such as benign prostatic hyperplasia and prostatic carcinoma.
    Type: Application
    Filed: May 7, 2002
    Publication date: May 15, 2003
    Applicant: Schering Corporation
    Inventors: Michael W. Leach, Mark R. Berardi, Elmer J. Mirro, Dineshwar Sinha, Jonathan A. Pachter, Mark E. Cartwright, Gregory A. Reichard
  • Method of treating androgen-dependent disorders
    Publication number: 20020165195
    Abstract: Novel methods of treating subjects afflicted with an androgen-dependent disorder, such as prostate cancer and benign prostatic hyperplasia are disclosed. Specifically, methods of treating androgen-dependent disorders by introducing a polypeptide or a polynucleotide encoding the polypeptide, which enhances inactivation of active androgens, are described.
    Type: Application
    Filed: May 1, 2002
    Publication date: November 7, 2002
    Applicant: Schering Corporation
    Inventors: Lynn Wang, Richard W. Bond, Jonathan A. Pachter
  • Hydro-ethano-indeno-pyridines
    Patent number: 5461057
    Abstract: A compound of formula I ##STR1## wherein X, V, W, Y, Z, R, a, b, c, and d are as described herein. These compounds are useful in the treatment of tumors, allergies, bronchoconstriction and CNS diseases and conditions.
    Type: Grant
    Filed: September 8, 1994
    Date of Patent: October 24, 1995
    Assignee: Schering Corporation
    Inventors: Joel G. Berger, David J. Blythin, Ronald J. Doll, Jonathan A. Pachter